Protocol Ledger

NCT05405114 · Phase II · COMPLETED

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

Interventional Phase II clinical trial protocol NCT05405114 sponsored by Novo Nordisk in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-07-07 Enrollment: 96 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05405114
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)96 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05405114
Protocol FieldVerified Registry Value
NCT IdentifierNCT05405114
Consolidated Lead SponsorNovo Nordisk
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment96 participants (ACTUAL)
Registered Start Date2022-07-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05405114
Hospital Research SiteLocationSite Profile
USC Norris Comprehensive Cancer Center and Keck MedicineLos Angeles, CAOpen Hospital Dossier ->
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI